Praxis Precision Medicines, Inc.
NASDAQ:PRAXBiotechnology
+$12.13 today
- Market cap
- $8.53B
- Beta
- 2.75
- P/E (TTM)
- -25.0
- EPS (TTM)
- -$11.31
Volume 0.43M
Average 0.45M
PRAX Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
Praxis Precision Medicines, Inc.NASDAQ: PRAX
Cash & Equivalents · Q3 FY2026 · quarter ended Sep 2026
Cash & equivalents rises 142.0% from a year ago
Cash & equivalents stood at $361.85M at the end of Q3 FY2026, up 142.0% from a year earlier and down 23.8% from the prior quarter. Over 3 fiscal years it compounded at +79.7% a year.
Context
- Cash & equivalents amounted to 27.6% of total assets at the end of Q3 FY2026, down 10.1 pp from a year earlier.
- Cash & equivalents increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +142.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 357.33M USD
- Year-over-year change
- +65.9%
- 4-year CAGR
- +26.7%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 357.33M | +65.9% |
| FY2024 | 2024-12-31 | 215.37M | +164.9% |
| FY2023 | 2023-12-31 | 81.3M | +31.9% |
| FY2022 | 2022-12-31 | 61.62M | -55.6% |
| FY2021 | 2021-12-31 | 138.7M | — |
Cash & Equivalents vs competitors
How PRAX compares with its peers on the latest reported figures
- PRAX's Sep 2026 cash & equivalents of $361.85M is the 3rd highest of the 10 companies compared; the peer median is $179.95M.
- Its year-over-year change of +142.0% is the 2nd highest of 10, against a peer median of +24.4%.
- Cash & equivalents amounts to 27.6% of total assets for PRAX, versus a peer median of 17.4%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | $976.45M | +278.5% | +15.7% | 54.4% | |
| Sep 2026 | $641.5M | +88.6% | +39.5% | 11.4% | |
| Sep 2026 | $361.85M | +142.0% | +79.7% | 27.6% | |
| Jun 2026 | $319.85M | +5.6% | +17.2% | 42.0% | |
| Jun 2026 | $201.53M | +42.7% | -2.0% | 17.4% | |
| Jun 2026 | $179.95M | +24.4% | +11.3% | 12.6% | |
NMRANeumora Therapeutics, Inc. Common Stock | Mar 2026 | $147.07M | +15.9% | -8.8% | 95.6% |
| Dec 2025 | $131.75M | +9.1% | -11.7% | 99.1% | |
| Sep 2026 | $82.56M | -21.0% | +51.5% | 6.9% | |
RAPPRapport Therapeutics, Inc. Common Stock | Mar 2026 | $78.06M | +35.5% | +19.1% | 15.7% |
| Peer median (excluding PRAX) | $179.95M | +24.4% | +15.7% | 17.4% | |
Competitors are the stored peer set for PRAX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 138.7M | 61.62M | 81.3M | 215.37M | 357.33M |
| Short-term Investments | 137.21M | 38.87M | 0 | 177.2M | 242M |
| Net Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 0 | 3.58M | 11.81M | 11.58M |
| Total Current Assets | 287.41M | 110.84M | 84.88M | 404.37M | 610.91M |
| Property, Plant & Equipment (Net) | 4.87M | 3.87M | 2.65M | 1.36M | 239K |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 76.96M | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 472K | 416K | 416K | 416K | 326.76M |
| Total Non-current Assets | 5.34M | 4.29M | 3.07M | 78.74M | 327M |
| Total Assets | 292.75M | 115.13M | 87.95M | 483.11M | 937.91M |
| Account Payables | 10.78M | 14.67M | 5.82M | 12.53M | 24.63M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 2.82M | 1.39M | 0 | 0 |
| Other Current Liabilities | 7.18M | 2.8M | 3.7M | 9.37M | 18.71M |
| Total Current Liabilities | 38.43M | 34.35M | 15.75M | 37.55M | 59.77M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 2.18M | 1.16M | 0 | 0 |
| Other Non-current Liabilities | 0 | 0 | 0 | 0 | 0 |
| Total Non-current Liabilities | 3.5M | 4.68M | 2.53M | 110K | 0 |
| Total Liabilities | 41.94M | 39.02M | 18.28M | 37.66M | 59.77M |
| Common Stock | 5K | 5K | 13K | 14K | 15K |
| Retained Earnings | (316.62M) | (530.64M) | (653.92M) | (836.74M) | (1.14B) |
| Accumulated OCI | (176K) | (173K) | 0 | 654K | 563K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 250.81M | 76.11M | 69.67M | 445.45M | 878.14M |
| Total Debt | 4.31M | 3.5M | 2.5M | 1.37M | 110K |
| Net Debt | (134.39M) | (58.12M) | (78.81M) | (214M) | (357.22M) |
Praxis Precision Medicines, Inc.
NASDAQ:PRAX
Intrinsic Alpha fair value
Locked
Current Price
$305.19
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.